HÁJEK, Roman, Zdeněk KOŘÍSTEK, J. VINKLÁRKOVÁ, E. JANOVSKÁ, Martin KLABUSAY, M. DOUBEK, D. DVOŘÁKOVÁ, L. BOURKOVÁ, L. DUŠEK, J. ADLER, Jiří MAYER and Jiří VORLÍČEK. Aktivace autologních transplantátů hematopoetických kmenových buněk interleukinem 2 (Activation of autologous hematopoietic stem cell transplants with interleukin-2). Časopis lékařů českých. Praha: Česká lékařská společnost J. Ev. Purkyně, 2001, vol. 140, No 14, p. 430-435. ISSN 0008-7335.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Aktivace autologních transplantátů hematopoetických kmenových buněk interleukinem 2
Name in Czech Aktivace autologních transplantátů hematopoetických kmenových buněk interleukinem 2
Name (in English) Activation of autologous hematopoietic stem cell transplants with interleukin-2
Authors HÁJEK, Roman (203 Czech Republic, guarantor), Zdeněk KOŘÍSTEK (203 Czech Republic), J. VINKLÁRKOVÁ (203 Czech Republic), E. JANOVSKÁ (203 Czech Republic), Martin KLABUSAY (203 Czech Republic), M. DOUBEK (203 Czech Republic), D. DVOŘÁKOVÁ (203 Czech Republic), L. BOURKOVÁ (203 Czech Republic), L. DUŠEK (203 Czech Republic), J. ADLER (203 Czech Republic), Jiří MAYER (203 Czech Republic) and Jiří VORLÍČEK (203 Czech Republic).
Edition Časopis lékařů českých, Praha, Česká lékařská společnost J. Ev. Purkyně, 2001, 0008-7335.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Organization unit Faculty of Medicine
Keywords (in Czech) IL-2; autologní transplantace; kmenové buňky
Keywords in English interleukin-2; autologous transplantation; stem cell
Tags autologous transplantation, interleukin-2, stem cell
Changed by Changed by: Mgr. Anna Potáčová, Ph.D., učo 44190. Changed: 23/6/2009 17:20.
Abstract
V publikaci je popsána metodika a výsledky aktivace hematopoetických buněk pomocí IL-2.
Abstract (in English)
Recent findings of the role of the immunity in eradication of residual tumour tissue after autologous transplantation rejection leading to extensive studies on T-cell mediated specific antitumor effects or nonspecific NL-cell mediated anticancer effects. We have evaluated on the methods of adoptive cell therapy IL-2 activation of autologous graft in the preclinical conditions. In laboratory conditions we have manipulated with autologous grafts form patients suffering with chronic myelocytic leukemia and patients suffering with multiple myeloma.We have proved the possibility to use IL-2 activated autologous graft in the clinical conditions. Based on our preclinical results experimental clinical trials have been initiated in patients suffering from chronic myelocytic leukemia and multiple myeloma.
PrintDisplayed: 22/5/2024 10:41